Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TK2 | O00142 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198346 | 0.90 | P2RY6 (0.46) | LMNASMN1; SMN2TK2TSHRMAPT | |
| SCHEMBL6536580 | 0.89 | LMNA (0.51) | LMNASMN1; SMN2TK2TSHRMAPT | |
| SCHEMBL18503453 | 0.88 | TK2 (0.59) | LMNATK2TYMP | |
| SCHEMBL7806784 | 0.86 | TK2 (0.54) | LMNASMN1; SMN2TK2TSHRMAPT | |
| SCHEMBL10895353 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2TK2TSHRMAPT | |
| SCHEMBL18503429 | 0.83 | P2RY6 (0.51) | P2RY6P2RY14NT5E | |
| SCHEMBL18503443 | 0.82 | SLC28A1 (0.57) | LMNASMN1; SMN2P2RY6P2RY14 | |
| SCHEMBL1055675 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL2583193 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL18503498 | 0.81 | P2RY6 (0.38) | LMNASMN1; SMN2TK2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | LMNA 1072/4885SMN1; SMN2 166/4885TK2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.